<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634282</url>
  </required_header>
  <id_info>
    <org_study_id>262-09-002</org_study_id>
    <nct_id>NCT01634282</nct_id>
  </id_info>
  <brief_title>Along-term Study of OPC-262 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Long-term Clinical Study of OPC-262 in Patients With Type 2 Diabetes on Study (Extension From Study 262-09-001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety of OPC-262 (2.5 mg and 5 mg) in&#xD;
      patients with type 2 diabetes by long-term administration orally for 52 weeks and to evaluate&#xD;
      the efficacy of OPC-262&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HBA1c form baseline</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Diabetes, Type 2</condition>
  <arm_group>
    <arm_group_label>OPC-262</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-262</intervention_name>
    <description>Orally administered once daily</description>
    <arm_group_label>OPC-262</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who completed Study 262-09-001 (namely, patients who visited the hospital at&#xD;
             visit Week 24ï¼‰&#xD;
&#xD;
          -  Patients who are capable of giving informed consent prior to participating in this&#xD;
             clinical study&#xD;
&#xD;
          -  Patients who are able to take contraceptive measures to avoid pregnancy of the patient&#xD;
             or the patient's partner for the entire study period and for 4 weeks after the study&#xD;
             (end of the post-observation period)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who withdrew from Study 262-09-001&#xD;
&#xD;
          -  Patients who experienced serious adverse events that the relationship with the study&#xD;
             drug was not denied in Study 262-09-001&#xD;
&#xD;
          -  Patients who experienced serious adverse events that the relationship with the study&#xD;
             drug are denied in Study 262-09-001 and whose symptoms are still emerged at the time&#xD;
             of initiation of this study&#xD;
&#xD;
          -  Patients who met the exclusion criteria of Study 262-09-001 during the study period of&#xD;
             Study 262-09-001&#xD;
&#xD;
          -  Female patients who wish to become pregnant during the study period of Study&#xD;
             262-09-002 or within 4 weeks after the study&#xD;
&#xD;
          -  Patients otherwise judged by the investigator or subinvestigator to be inappropriate&#xD;
             for inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>July 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

